Immune Checkpoint Inhibitors in NSCLC: Experts Address Clinical Challenges to Clarify Optimal Use

Immune Checkpoint Inhibitors in NSCLC: Experts Address Clinical Challenges to Clarify Optimal Use

Sunday, June 4, 2017 in Chicago, IL
Dinner -- Hilton Chicago, 6:30 PM CST
Continental A-B-C


7:00 PM Welcome and Program Overview

7:05 PM Overview of the Current Status of Checkpoint Inhibitors in NSCLC

7:25 PM Application in the Clinic: Use of Immune Checkpoint Inhibitors in Advanced NSCLC

  • Progressive disease and treatment choice
  • Newly diagnosed disease and patient identification
  • Toxicity management and optimizing duration

8:30 PM Future Directions in Immunotherapy for NSCLC

8:50 PM Closing Remarks


Program Director
H. Jack West, MD

Hossein Borghaei, MS, DO

The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Leena Gandhi, MD

Associate Professor of Medicine
Division of Medicine
Perlmutter Cancer Center
New York University School of Medicine
Director, Thoracic Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Medical Center
New York, New York

Edward Garon, MD

Associate Clinical Professor
Thoracic Oncology Program
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Suresh Ramalingam, MD

Professor of Hematology and Medical Oncology
Roberto C. Goizueta Chair for Cancer Research
Division of Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, Georgia

Goal Statement
The goal of this activity is to improve participants’ competence in and performance at integrating immunotherapies into treatment strategies for patients with lung cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives

  • Plan treatment strategies for patients with NSCLC and disease progression on or after platinum-containing chemotherapy based on available data, treatment guidelines, and expert recommendations
  • Compare atezolizumab, nivolumab, and pembrolizumab as second-line therapy for patients with metastatic NSCLC
  • Evaluate the therapeutic impact of pembrolizumab as a first-line treatment of patients with advanced NSCLC and high PD-L1 expression
  • Use available biomarkers of response to identify patients with advanced NSCLC who may benefit from immune checkpoint inhibitor therapy
  • Manage immune-related adverse events in patients with advanced NSCLC on checkpoint inhibitor therapy
  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of clinical care strategies for NSCLC
  • Describe the role of combination approaches to optimize checkpoint inhibitor efficacy and reduce treatment resistance



Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.